ImmunoPrecise Antibodies【IPA】銘柄情報

ImmunoPrecise Antibodies Ltd (IPA) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

6.50

( - )

買値

6.31

売値

6.75

出来高

0.00 日の範囲 0.00

0.00 52 週間の範囲 0.00

時価総額

322.831M

前日終値

6.50

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

$ 342,188

発行済株式数

49,666,372

配当利回り

PER

-9.16

1 株当たり利益 (EPS)

-0.27

歳入

28.08M

純利益

-12.25M

MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partner... MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company was incorporated in 1983 and is headquartered in Austin, Texas. 詳細を表示

セクター

業界

ウェブサイト

www.mindwalkai.com

本社

Austin, United States

設立

1983

ImmunoPrecise Antibodies Ltd is listed in the sector of the トロントベンチャー取引所 with ticker IPA. The last closing price for ImmunoPrecise Antibodies was $6.50. Over the last year, ImmunoPrecise Antibodies shares have traded in a share price range of $ 0.00 to $ 0.00.

ImmunoPrecise Antibodies currently has 49,666,372 shares in issue. The market capitalisation of ImmunoPrecise Antibodies is $322.83 million. ImmunoPrecise Antibodies has a price to earnings ratio (PE ratio) of -9.16.

IPA's Subsidiary BioStrand Secures Second VLAIO Research Grant

IPA's Subsidiary BioStrand Secures Second VLAIO Research GrantIPA subsidiary BioStrand receives grant to expand LENSai platform by linking...

IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue - Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings

IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue – Adding Artificial Intelligence-Driven Analytics...

IPA Announces Agreement to Acquire BioStrand BV - Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence

IPA Announces Agreement to Acquire BioStrand BV - Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with...

IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from Defense Health Agency within US Department of Defense

IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from...

IPA Updates on Investigational New Drug (IND) Enabling Program for PolyTope® TATX-03

IPA Updates on Investigational New Drug (IND) Enabling Program for PolyTope® TATX-03 In vivo, IND enabling evaluations of PolyTope®...

ImmunoPrecise lance le programme d'anticorps candidat TATX-112 pour le traitement du cancer et de la maladie d'Alzheimer

Traitement potentiel de la maladie de Parkinson et d'autres affections neurodégénératives IMMUNOPRECISE ANTIBODIES LTD. (la "Société" ou "IPA...

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer's Disease

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer's...

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer’s Disease

Potential to Treat Parkinson’s and Other Neurodegenerative Diseases IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX...

ImmunoPrecise identifie un anticorps unique, le 23-H7, qui démontre une efficacité in vivo, un mécanisme d'action alternat...

L'anticorps bloque l'interaction de liaison DFR/ACE2 par le biais d'un mécanisme d'action alternatif L'anticorps se lie à tous les variants...

ImmunoPrecise Identifies a Unique Antibody, 23-H7, That Demonstrates In Vivo Efficacy, an Alternative Mechanism of Action & B...

Blocks the RBD/ACE2 binding interaction indirectly through an alternative mechanism of action Binds to all tested variants of concern, likely...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

IPA - Frequently Asked Questions (FAQ)

What is the current ImmunoPrecise Antibodies Ltd share price?

The current share price of ImmunoPrecise Antibodies Ltd is $ 6.50

How many ImmunoPrecise Antibodies Ltd shares are in issue?

ImmunoPrecise Antibodies Ltd has 49,666,372 shares in issue

What is the market cap of ImmunoPrecise Antibodies Ltd?

The market capitalisation of ImmunoPrecise Antibodies Ltd is CAD 322.83M

What is the 1 year trading range for ImmunoPrecise Antibodies Ltd share price?

ImmunoPrecise Antibodies Ltd has traded in the range of $ 0.00 to $ 0.00 during the past year

What is the PE ratio of ImmunoPrecise Antibodies Ltd?

The price to earnings ratio of ImmunoPrecise Antibodies Ltd is -9.16

What is the cash to sales ratio of ImmunoPrecise Antibodies Ltd?

The cash to sales ratio of ImmunoPrecise Antibodies Ltd is 4.14

What is the registered address of ImmunoPrecise Antibodies Ltd?

The registered address for ImmunoPrecise Antibodies Ltd is Industrious 823 Congress Ave, Austin, Texas, 78701

What is the ImmunoPrecise Antibodies Ltd website address?

The website address for ImmunoPrecise Antibodies Ltd is www.mindwalkai.com

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

ImmunoPrecise Antibodies Ltd (IPA)

ImmunoPrecise Antibodies Ltd (IPA) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

ImmunoPrecise Antibodies Ltd について

IPA 最新ニュース

IPA's Subsidiary BioStrand Secures Second VLAIO Research Grant

IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue - Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings

IPA Announces Agreement to Acquire BioStrand BV - Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence

IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from Defense Health Agency within US Department of Defense

IPA Updates on Investigational New Drug (IND) Enabling Program for PolyTope® TATX-03

ImmunoPrecise lance le programme d'anticorps candidat TATX-112 pour le traitement du cancer et de la maladie d'Alzheimer

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer's Disease

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer’s Disease

ImmunoPrecise identifie un anticorps unique, le 23-H7, qui démontre une efficacité in vivo, un mécanisme d'action alternat...

ImmunoPrecise Identifies a Unique Antibody, 23-H7, That Demonstrates In Vivo Efficacy, an Alternative Mechanism of Action & B...

IPA - Frequently Asked Questions (FAQ)

IPA 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

ImmunoPrecise Antibodies Ltd (IPA)

ImmunoPrecise Antibodies Ltd (IPA) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

ImmunoPrecise Antibodies Ltd について

IPA 最新ニュース

IPA's Subsidiary BioStrand Secures Second VLAIO Research Grant

IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue - Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings

IPA Announces Agreement to Acquire BioStrand BV - Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence

IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from Defense Health Agency within US Department of Defense

IPA Updates on Investigational New Drug (IND) Enabling Program for PolyTope® TATX-03

ImmunoPrecise lance le programme d'anticorps candidat TATX-112 pour le traitement du cancer et de la maladie d'Alzheimer

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer's Disease

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer’s Disease

ImmunoPrecise identifie un anticorps unique, le 23-H7, qui démontre une efficacité in vivo, un mécanisme d'action alternat...

ImmunoPrecise Identifies a Unique Antibody, 23-H7, That Demonstrates In Vivo Efficacy, an Alternative Mechanism of Action & B...

IPA - Frequently Asked Questions (FAQ)

IPA 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

無料で登録してください:

広告を削除する

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS